Genmab AS (CHIX:GMABC) Growth Rank: 10 (As of Aug. 31, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:GMABC Genmab AS CHIX:GMABC
97 GF Score
Price kr2,163.00
GF Value kr2,152.09
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Genmab AS Growth Rank?

Genmab AS CHIX:GMABC 97 Growth Rank is 10 as of Aug. 31, 2026, which is at its 10-year median of 10.00. GuruFocus rates CHIX:GMABC with a GF Score™ of 97/100 and a GF Value™ of kr2,152.09 (Fairly Valued). The stock has 6 warning signs investors should review.

Genmab AS has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

CHIX:GMABC vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, Genmab AS's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genmab AS Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Growth Rank distribution charts can be found below:

* The bar in red indicates where Genmab AS's Growth Rank falls into.


CHIX:GMABC
97GF Score
Genmab AS CHIX:GMABC
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Genmab AS (CHIX:GMABC) has a Growth Rank of 10 as of Aug. 31, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Genmab AS and its competitors. This is near median its historical median of 10.00. Over the past decade, Genmab AS's Growth Rank has ranged from 7.00 to 10.00.
Is Genmab AS's Growth Rank too high?
Genmab AS's current Growth Rank of 10 is near median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 10.00. Overall, Genmab AS has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Growth Rank compare to VRTX and REGN?
Genmab AS's Growth Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Genmab AS's own Growth Rank has ranged from 7.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Genmab AS and its competitors. Genmab AS's current Growth Rank is 10, which is near median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Fairly Valued. The stock's GF Value™ is kr2,152.09, compared to a current price of kr2,163.00 — trading 0.5% above its estimated fair value. The current Growth Rank is 10, which is near median its 10-year median of 10.00. Genmab AS's overall GF Score™ is 97/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Growth Rank is 10 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (CHIX:GMABC) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be overvalued. The current stock price of kr2,163.00 is trading 0.5% above its estimated GF Value™ of kr2,152.09. GuruFocus considers Genmab AS to be Fairly Valued.

Key valuation signals for CHIX:GMABC:

  • Growth Rank: 10 (near median its 10-year median of 10.00)
  • GF Value™: kr2,152.09 vs. price of kr2,163.00 (0.5% above fair value)
  • GF Score™: 97/100 with 6 warning signs

No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
97GF Score

Get the complete analysis for CHIX:GMABC

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2,163.00
Price
kr2,152.09
GF Value